Articles tagged with Lung Cancer
Researchers found that Notch 1 is required for initial tumor growth and survival of cancer cells. Disabling Notch 1 leads to increased cancer cell death through increased p53 stability.
A study led by UT Southwestern Medical Center researchers found that total tumor measurements greater than 3 inches predict shorter survival times in advanced lung cancer patients. Patients with larger tumors live an average of 9.5 months, compared to 12.6 months for those with smaller tumors.
Researchers at Moffitt Cancer Center identified four genetic variants associated with increased risk of death in non-small cell lung cancer patients. These variants also indicate a greater risk of death if treatment plans include surgery without chemotherapy compared to those with chemotherapy following surgery.
Researchers found that a specific pattern in tumor pathology is strongly associated with cancer recurrence. Patients with this pattern are more likely to benefit from lobectomy and have a 75% lower risk of recurrence. The study may lead to new technology to precisely identify tumors with this pattern before surgery.
Researchers at Fred Hutchinson Cancer Center are pioneering a new approach to harness the power of the adaptive immune system to control cancer. They are using high-throughput technology and large-scale data mining to identify potential immune targets and verify their immunogenicity.
Screening asymptomatic high-risk adults for lung cancer using low-dose computed tomography (LDCT) may significantly reduce mortality, according to a systematic review. The US Preventive Services Task Force reviewed 67 articles and found that LDCT screening can detect lung cancer at an earlier stage, leading to lower mortality rates.
Researchers found that obese patients initially had superior outcomes in terms of overall survival compared to normal-weight and overweight patients. However, their risk of death from any cause significantly increased once they were on the study longer than 16 months, indicating a limited time benefit of obesity in lung cancer patients.
Researchers in Canada found that funding from the pharmaceutical industry significantly decreased EGFR mutation testing after it was discontinued. The Canadian healthcare system lacked resources for implementing a national policy, leading to a substantial drop in test requests.
Researchers have identified Ephrin B2 as a promising target for treating malignant pleural mesothelioma, a rare and aggressive form of lung cancer. The study found that EPHB2 is significantly overexpressed in tumor tissue compared to normal peritoneum, suggesting its potential as a biomarker for early diagnosis and treatment.
Researchers at Moffitt Cancer Center discovered a gene expression signature that may lead to new immune therapies for lung cancer patients. High levels of NF-κB in lung cancer tumors can act as a suppressor, boosting the immune system to eliminate cancerous cells.
A study by Weill Cornell Medicine found that even healthy-looking smokers have damaged airway cells with characteristics similar to those in aggressive lung cancer. The researchers discovered that these cells express human embryonic stem cell genes, which are normally only active in developing embryos.
A European-wide study found that prolonged exposure to particulate air pollution increases the risk of lung cancer, particularly adenocarcinoma, at concentrations below EU limit values. The analysis of 17 cohort studies involved over 313,000 people and found a strong association between air pollution and lung cancer risk.
The foundation awarded six new Clinical Investigators, including Omar Abdel-Wahab and Himisha Beltran, for their cancer research programs. The recipients will receive $450,000 each, while three others received Continuation Grants worth $300,000 to support ongoing research.
Researchers have developed two new methodologies to determine ALK status in non–small-cell lung cancer (NSCLC) patients. The first method improves IHC assay sensitivity using a novel hapten and tyramide amplification, detecting low levels of ALK protein expression. The second method combines brightfield IHC with in situ hybridization f...
Researchers developed a highly accurate method to detect ALK-rearranged non-small cell lung cancer using immunocytochemistry. The study found that this method had high sensitivity and specificity, making it suitable for prescreening NSCLC patients.
Anurag Singh, PhD, has received a $100,000 ALA Lung Cancer Discovery Grant to study targeted therapies for drug-resistant lung cancers. He aims to develop strategies to block KRAS protein function and improve treatment outcomes.
A study of 582 patients with stage I non-small cell lung cancer (NSCLC) found SBRT to be safe and effective, with a three-year freedom from local progression rate of 79.6%. The biological effective dosage was the most significant factor influencing outcomes.
A recent study found that lung cancer in women who have never smoked is more frequently associated with EGFR mutations and estrogen receptor (ER) overexpression. The researchers observed a higher percentage of these genetic abnormalities in patients who had not previously smoked, suggesting potential new treatment targets for this group.
Researchers evaluate immunohistochemistry for detecting ALK rearrangement in lung adenocarcinoma, finding it a reliable and cost-effective method. The study suggests that IHC can effectively detect ALK rearrangement and identify suitable candidates for targeted therapy.
Researchers at UT Dallas discovered that lung cancer cells consume more oxygen and synthesize a critical chemical called heme, which can be exploited to inhibit cancer growth. Inhibiting heme synthesis affects lung cancer cells' ability to proliferate and migrate.
A study by St. Jude Children's Research Hospital found that 98% of childhood cancer survivors have at least one chronic health condition, with 80% developing a life-threatening condition by age 45. Regular medical checkups and healthy lifestyle choices can help mitigate risk.
Dr. Matt Huentelman and Dr. Glen Weiss are among the 40 Under 40 honorees recognized by the Phoenix Business Journal for their contributions to genomic research, including TGen's MindCrowd project and lung cancer studies. The recognition highlights the institute's advancements in understanding human genetics and developing new treatments.
Researchers have discovered a new oncogene, NTRK1, that drives a subset of lung cancers. A novel targeted treatment approach has been proposed, with preclinical studies showing effective silencing of mutated NTRK1 genes using specific compounds.
Researchers have discovered a new oncogene, RET rearrangement, which is present in 15.7% of lung adenocarcinoma patients and may be targeted with existing tyrosine-kinase inhibitors. This finding presents a promising treatment option for patients with this specific mutation.
Researchers found that crizotinib boosts median disease progression time to 7.7 months, compared to 3 months with standard chemotherapy, in patients with non-small cell lung cancer harboring an abnormal ALK gene.
Two MGH-led studies show crizotinib is superior to chemotherapy for advanced ALK-positive non-small cell lung cancer, with over double the progression-free survival. A second study reports the first crizotinib resistance in a ROS1-positive lung tumor, revealing the mechanism underlying that resistance.
Researchers at Fox Chase Cancer Center are conducting further tests on the drug nivolumab, a monoclonal antibody that targets the immune system's response to cancer. The therapy appears to produce largely manageable side effects and has shown potential in treating tumors more effectively than current treatments.
Sarcomatoid lung carcinomas are rare and aggressive diseases resistant to chemotherapy. Researchers found higher levels of programmed death ligand-1 (PD-L1) in these tumors, which may lead to the use of anti-PD-1/PD-L1 targeted therapies. This discovery supports potential novel immunotherapy approaches for this difficult-to-treat disease.
Researchers have identified two ruthenium-based complexes that target cancer cells more effectively and are less toxic than current chemotherapies. The complexes, which seem to target cells in hypoxic states, could complement widely used platinum-based therapies like cisplatin.
A new LSUHSC paper has been selected as the Best Paper of the Year by the National Cancer Registrars Association for its innovative evaluation of cancer stages. The study found that lung and prostate cancers had the highest percentages of unknown stages, with non-hospital reporting sources being a key predictor.
A recent study published in the Journal of Thoracic Oncology found that digital chest tomosynthesis (DT) holds promise as a first-line lung cancer screening tool. DT improved sensitivity in detecting lung nodules compared to conventional chest radiography, while providing lower costs and radiation dosages.
Researchers have developed a new drug delivery system that uses nanoparticles and siRNA to target lung cancer cells, eliminating resistance and reducing systemic damage. In laboratory tests, the system showed significant improvement in treating lung tumors, with nearly 83% of the drug delivered directly to the lungs.
A new study confirms low-dose computed tomography (LDCT) detects more early-stage lung cancers than chest X-ray (CXR), supporting a 20% reduction in mortality. Compliant imaging facilities performed 98.5% of studies within protocol specifications.
A new study shows that minimal dose computed tomography (MnDCT) is more sensitive than conventional chest X-rays in detecting new or recurrent lung cancer, while delivering a similar amount of radiation. The study found that MnDCT detected 94% of recurrent cancers compared to 21%, allowing for earlier treatment and longer survival rates.
A new portable and real-time airborne asbestos detector has been developed using a laser-based light scattering technique. The device can identify asbestos fibers on-site, reducing the risk of lung cancers such as mesothelioma.
Researchers found that a combination of chemoradiation therapy and surgery improves overall survival in stage 3 non-small cell lung cancer patients. Five-year survival rates were twice as high for those who received chemoradiation followed by surgery compared to those who only had chemoradiation.
Researchers discovered that abnormal histone protein modification impairs DNA repair machinery, leading to a potential new way of detecting colorectal cancers. The study, published in Cell, reveals a novel mechanism explaining the root cause of some forms of colorectal cancers.
A retrospective study suggests that patients with lung cancer carrying specific HER2 mutations may experience tumor shrinkage and delayed disease progression when treated with anti-HER2 drugs. The study found 1.7% of NSCLC patients in Europe had these rare mutations, which can lead to continuous activation of the HER2 protein.
A recent study published in the Journal of Thoracic Oncology found that higher primary care provider density is associated with lower lung cancer mortality rates, particularly among white populations. The researchers suggest that interventions aimed at primary care providers may deserve more investigation to improve access to cancer care.
Researchers found that tumors with ALK gene rearrangements can harbor up to 20% of additional mutations, including EGFR and MET genes. These coexisting mutations may impact treatment response to targeted therapies.
Researchers found that intraventricular chemotherapy can palliate associated symptoms in patients with leptomeningeal carcinomatosis from non-small cell lung cancer. The study shows that 20 of 69 patients achieved normal ICP, and careful patient selection is recommended for successful treatment.
New research shows that mathematical prediction models, not doctors, are better at predicting the outcomes and responses of lung cancer patients to treatment. The models use information from previous patients to create a statistical formula that can be used to predict patient survival and response to treatment.
A new study found that combining asbestos exposure, asbestosis, and smoking significantly increases the risk of developing lung cancer. Quitting smoking can reduce this risk after long-term asbestos exposure.
Fox Chase researchers have discovered that nearly 6% of non-smoker lung cancer tissue samples show signs of HPV triggering the tumors. The study suggests a potential link between HPV and lung cancer, with implications for treatment and prognosis.
A new chemotherapy regimen combining Tarceva and Alisertib appears safe in patients with non-small cell lung cancer that has not responded to previous treatments. The study found minimal side effects and stabilization of tumors in some patients, paving the way for further research.
The new software tool, CANARY, uses data from existing CT images to match each pixel of the lung nodule to one of nine unique radiological exemplars. This classification method has an excellent correlation with microscopic analysis and may help address issues with current screening methods.
A recent study found that male smokers with low levels of serum bilirubin are at a higher risk of developing lung cancer and dying from the disease. The researchers analyzed data from over 435,000 people in Taiwan and found that lower bilirubin levels were associated with significantly higher rates of lung cancer incidence and mortality.
A team of researchers at UT Southwestern Medical Center has identified a specific genetic weakness in lung-cancer cells that can be targeted with new therapies. The discovery, published in Cancer Discovery, highlights the potential of blocking the protein RHOA and focal adhesion kinase (FAK) to stop tumor growth.
The International Association for the Study of Lung Cancer has developed a guideline for molecular testing in lung cancer, recommending testing for EGFR and ALK abnormalities in all patients with advanced lung adenocarcinoma. This approach provides individualized treatment options and improved quality of life for patients.
A survey by the IASLC found that 90% of physicians believe tobacco cessation is essential for lung cancer treatment, but only 39% provide assistance. The study highlights barriers to effective tobacco cessation support for cancer patients.
Ganetespib shows greater antitumor activity against ALK-positive NSCLC and overcomes crizotinib resistance in mice xenografted with human cancer cells. The drug is effective for treating patients who have become resistant to FDA-approved targeted therapy.
Researchers at Moffitt Cancer Center have developed a small molecule, S31-1757, that inhibits the ability of STAT3 to cause malignancy. This development could impact the treatment of several tumor types, including breast, lung, prostate and others that depend on STAT3 for survival.
Researchers developed a mathematical model to analyze lung cancer spread patterns, revealing that cancer cells move around the body in multiple directions. The study identified specific areas of the body as 'spreaders' and 'sponges,' which could guide physicians to targeted treatment options.
A large observational follow-up study found that women with lung cancer who consumed more soy food prior to diagnosis lived longer. Soy contains isoflavones that may affect molecular pathways involved in tumor development and growth.
A study published by the International Association for the Study of Lung Cancer found that 54% of patients with early stage node-negative lung adenocarcinoma had tumors with at least one biologically relevant mutation. The researchers also discovered mutations associated with drug resistance in these patients.
A new study estimates that LDCT screening for lung cancer can delay or prevent approximately 12,000 deaths each year in the United States. The potential benefits of widespread LDCT screening are significant, given that half of current smokers will die from smoking-related diseases.
Researchers found local therapy combined with continued EGFR TKI therapy to be well-tolerated and effective in prolonging progression-free and overall survival. Local therapy was associated with a median overall survival of 41 months, a median time to progression of 10 months.
A study found that elderly patients are significantly underrepresented in clinical trials, with only 33% of highly cited trials excluding them. Researchers recommend increasing age diversity to better represent the median age of advanced NSCLC patients.
Researchers at Moffitt Cancer Center have identified IKBKE kinase as a potential targeted therapy for patients with tobacco-associated non-small cell lung cancer. The study suggests that IKBKE overexpression is induced by tobacco smoke and can be targeted to reduce cancer progression.
Researchers found that cigarette smoke-induced miRNA alterations promote lung carcinogenesis by repressing miR-487b. Additionally, high levels of ox-CaMKII are linked to increased risk of sudden death after heart attack in diabetic patients, suggesting a potential mechanism for increased mortality.